​

LENZ Therapeutics Ownership | Who Owns LENZ Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

LENZ Therapeutics Ownership Summary

LENZ Therapeutics is owned by 23.75% institutional investors, 2.65% insiders, and 73.60% retail investors. Ra capital management is the largest institutional shareholder, holding 13.45% of LENZ shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.26% of its assets in LENZ Therapeutics shares.

LENZ Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockLENZ Therapeutics23.75%2.65%73.60%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management4.18M13.45%$38.24M
Alpha wave global, lp3.61M11.63%$33.05M
Fmr3.60M11.58%$32.92M
Versant venture management2.66M8.55%$24.31M
Blackrock funding, inc. /de1.98M6.36%$18.09M
Squarepoint ops1.51M4.85%$13.78M
Vanguard group1.32M4.63%$21.14M
Paradigm biocapital advisors lp1.07M3.82%$50.00M
Abrdn1.16M3.72%$10.58M
Franklin resources1.10M3.54%$10.07M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
72 investment1.02M18.77%$9.31M
Versant venture management2.66M17.19%$24.31M
Ally bridge group (ny)175.36K4.97%$8.17M
Alpha wave global, lp3.61M4.18%$33.05M
Saturn v capital management368.18K3.76%$17.15M
First light asset management693.04K3.04%$32.28M
Samsara biocapital343.01K2.09%$15.98M
Intrinsic edge capital management569.71K1.62%$9.12M
Paradigm biocapital advisors lp1.07M1.42%$50.00M
Blue owl capital lp506.72K1.25%$4.64M

Top Buyers

HolderShares% AssetsChange
Squarepoint ops1.51M0.02%1.01M
First light asset management693.04K3.04%693.04K
Abrdn1.16M0.02%666.73K
Intrinsic edge capital management569.71K1.62%569.71K
Morgan stanley648.85K0.00%415.47K

Top Sellers

HolderShares% AssetsChange
Ubs group156.99K0.00%-1.41M
Price t rowe associates inc /md/39.62K--983.92K
Paradigm biocapital advisors lp1.07M1.42%-643.61K
Adage capital partners gp627.62K0.05%-495.12K
Granahan investment management---431.10K

New Positions

HolderShares% AssetsChangeValue
First light asset management693.04K3.04%693.04K$32.28M
Intrinsic edge capital management569.71K1.62%569.71K$9.12M
Vanguard fiduciary trust149.99K0.00%149.99K$1.37M
Aqr capital management140.31K0.00%140.31K$1.28M
Affinity asset advisors100.00K0.05%100.00K$915.00K

Sold Out

HolderChange
Stephens consulting-1.00
Signaturefd-9.00
Rise advisors-15.00
Coldstream capital management-16.00
Steward partners investment advisory-19.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202665-61.08%7,379,217-78.96%230.16%44-57.69%10-68.75%
Dec 31, 2025106-38.01%19,426,586-33.34%680.63%64-46.67%21-12.50%
Sep 30, 202516238.46%28,801,56716.48%1021.32%11543.75%2364.29%
Jun 30, 202511610.48%24,721,51417.75%881.51%7943.64%14-46.15%
Mar 31, 202510616.48%21,119,1009.06%761.51%575.56%2630.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S1.65M5.26%2.05K
Fidelity Growth Company Fund1.23M3.92%-
Vanguard Total Stock Mkt Idx Inv819.61K2.61%57.45K
abrdn Healthcare Investors784.39K2.50%-
C WorldWide Healthcare Select 1A700.00K2.23%200.00K
iShares Russell 2000 ETF461.96K1.47%3.90K
PRIMECAP Odyssey Aggressive Growth406.40K1.30%85.40K
Candriam Eqs L Biotech C USD Cap374.93K1.20%134.00K
abrdn Life Sciences Investors371.77K1.19%-
Fidelity Series Growth Company362.10K1.15%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 27, 2026George Jeffrey P.-Buy$49.89K
Mar 27, 2026Schimmelpennink Evert B. President, CEO and SecretaryBuy$251.41K
Mar 27, 2026Chevallard Daniel R. Chief Financial OfficerBuy$64.28K
Nov 17, 2025Olsson Shawn Chief Commercial OfficerSell$108.41K
Nov 17, 2025Olsson Shawn Chief Commercial OfficerSell$152.61K

Insider Transactions Trends

DateBuySell
2025 Q432
2025 Q3-29
2025 Q2-5
2025 Q1--
2024 Q4--

LENZ Ownership FAQ

Who Owns LENZ Therapeutics?

LENZ Therapeutics shareholders are primarily institutional investors at 23.75%, followed by 2.65% insiders and 73.60% retail investors. The average institutional ownership in LENZ Therapeutics's industry, Biotech Stocks , is 35.75%, which LENZ Therapeutics falls below.

Who owns the most shares of LENZ Therapeutics?

LENZ Therapeutics’s largest shareholders are Ra capital management (4.18M shares, 13.45%), Alpha wave global, lp (3.61M shares, 11.63%), and Fmr (3.6M shares, 11.58%). Together, they hold 36.65% of LENZ Therapeutics’s total shares outstanding.

Does Blackrock own LENZ Therapeutics?

BlackRock is not among the top 10 institutional shareholders of LENZ Therapeutics.

Who is LENZ Therapeutics’s biggest shareholder by percentage of total assets invested?

72 investment is LENZ Therapeutics’s biggest shareholder by percentage of total assets invested, with 18.77% of its assets in 1.02M LENZ Therapeutics shares, valued at 9.31M$.

Who is the top mutual fund holder of LENZ Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of LENZ Therapeutics shares, with 5.26% of its total shares outstanding invested in 1.65M LENZ Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools